Covid-19: WHO to publish conclusions on the efficacy of hydroxychloroquine in two weeks

• June, 1 2020 à 17:10
• Jean-Claude Dorsainvil
• Santé
• 0 Comments

WHO has suspended temporary testing for hydroxychloroquine for safety reasons. The UN agency also announced the launch of a digital platform to share data, information and intellectual property on tools to fight the disease.

Monday, June 1, 2020 (haitiinfoonline.net) - The solidarity trial, which brings together international partners to test treatments against Covid-19, has temporarily suspended analyzes on the efficacy of hydroxychloroquine, announced on Friday World Health Organization (WHO).

In a note, the UN agency said the decision was made by the executive group leading the initiative and motivated by research published in the scientific journal The Lancet, among other factors.

According to WHO, the safety data is being reviewed. A final decision on the harmful and beneficial effects of the medicine will be made by the Data Security Supervisory Board.

The findings of the review, which will include information from the solidarity trial, other research in progress and some already completed, are expected by mid-June.

Sharing data and knowledge
This Friday, WHO launched C-TAP, a platform for the open sharing of knowledge, data and intellectual property on tools to combat Covid-19.

Speaking to journalists in Geneva, WHO Director-General Tedros Ghebreyesus said "science is evolving at an incredible speed".

According to him, "hardly a day goes by without the announcement of news on research into vaccines, diagnostics and therapies. The world will benefit from these tools or if they will not become another reason for that some people are forgotten.

The C-TAP initiative has the support of 35 countries and many partners. This tool complements the ACT Accelerator project, launched last month to accelerate the development, production and equitable distribution of vaccines, diagnostics and treatments.